azd-6244 and Mouth-Neoplasms

The lack of advanced animal models of human cancers is considered a barrier to developing effective therapeutics. Canine and human melanomas are histologically disparate but show similar disease progression and response to therapies. The purpose of these studies was to compare human and canine melanoma tumours and cell lines regarding MAPK and PI3K/AKT signalling dysregulation, and response to select molecularly targeted agents. Pathway activation was investigated via microarray and mutational analysis. Growth inhibition and cell cycle effects were assessed for pathway inhibitors AZD6244 (MAPK) and rapamycin (PI3K/AKT) in human and canine melanoma cells. Human and canine melanoma share similar differential gene expression patterns within the MAPK and PI3K/AKT pathways. Constitutive pathway activation and similar sensitivity to AZD6244 and rapamycin was observed in human and canine cells. These results show that human and canine melanoma share activation and sensitivity to inhibition of cancer-related signalling pathways despite differences in activating mutations.

Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Benzimidazoles; Cell Line, Tumor; Databases, Genetic; Dog Diseases; Dogs; GTP Phosphohydrolases; Humans; Melanoma; Membrane Proteins; Mitogen-Activated Protein Kinase Kinases; Mouth Neoplasms; Mutation; Oncogene Protein v-akt; Polymerase Chain Reaction; Proto-Oncogene Proteins B-raf; Signal Transduction; Sirolimus; Tissue Array Analysis